One-year Clinical Observation on Combination of Telbivudine and Adefovir in Treatment of HBeAg Positive Chronic Hepatitis B Patients

Objective To determine the efficacy and safety of telbivudine and adefovir combination therapy on HBeAg positive chronic hepatitis B patients.Methods 216 HBeAg positive chronic hepatitis B patients admitted to our department were randomly divided into 3 groups: telbivudine and adefovir combination therapy group(group A,72 patients),telbivudine therapy group(group B,72 patients) and adefovir therapy group(group C, 72 patients).The efficacy at 12th,24th,36th and 48th week was carefully analyzed.Result Group A was found to have higher HBV DNA negative rate,higher HBeAg serum conversion rate,and more ALT normalization than group B and C,the difference was statistically significant(P0.05).Conclusion According to our one-year observation,therapeutic strategy with telbivudine and adefovir combination in HBeAg positive chronic hepatitis B patients has higher efficacy and safety and lower drug resistance,which is strongly recommended.